APVO711 / Aptevo Therap - LARVOL DELTA

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation (ACCESSWIRE) - "As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR platform; In preclinical studies, APVO711 demonstrates dual anti-cancer functionality with broad solid tumor potential and developability."

Clinical data • Preclinical • Acute Myelogenous Leukemia • Solid Tumor

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors (Aptevo Therapeutics Press Release) - "Aptevo Therapeutics Inc...announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon. The Company plans to initiate pre-clinical studies this year."

Patent • Preclinical • Colon Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck